Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep 24;79(1):65–71. doi: 10.1038/sj.bjc.6690013

A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245)

F Degorce 1, Y Goumon 2, L Jacquemart 1, C Vidaud 1, L Bellanger 1, D Pons-Anicet 1, P Seguin 1, M H Metz-Boutigue 2, D Aunis 2
PMCID: PMC2362168  PMID: 10408695

Abstract

Chromogranin A (CgA), a major protein of chromaffin granules, has been described as a potential marker for neuroendocrine tumours. Because of an extensive proteolysis which leads to a large heterogeneity of circulating fragments, its presence in blood has been assessed in most cases either by competitive immunoassays or with polyclonal antibodies. In the present study, 24 monoclonal antibodies were raised against native or recombinant human CgA. Their mapping with proteolytic peptides showed that they defined eight distinct epitopic groups which spanned two-thirds of the C-terminal part of human CgA. All monoclonal antibodies were tested by pair and compared with a reference radioimmunoassay (RIA) involving CGS06, one of the monoclonal antibodies against the 198–245 sequence. It appears that CgA C-terminal end seems to be highly affected by proteolysis and the association of C-terminal and median-part monoclonal antibodies is inadequate for total CgA assessment. Our new immunoradiometric assay involves two monoclonal antibodies, whose contiguous epitopes lie within the median 145–245 sequence. This assay allows a sensitive detection of total human CgA and correlates well with RIA because dibasic cleavage sites present in the central domain do not seem to be affected by degradation. It has been proved to be efficient in measuring CgA levels in patients with neuroendocrine tumours. © 1999 Cancer Research Campaign

Keywords: chromogranin A, monoclonal antibodies, epitope mapping, proteolysis, immunoradiometric assa

Full Text

The Full Text of this article is available as a PDF (76.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bader M. F., Aunis D. The 97-kD alpha-actinin-like protein in chromaffin granule membranes from adrenal medulla: evidence for localization on the cytoplasmic surface and for binding to actin filaments. Neuroscience. 1983 Jan;8(1):165–181. doi: 10.1016/0306-4522(83)90036-2. [DOI] [PubMed] [Google Scholar]
  2. Barbosa J. A., Gill B. M., Takiyyuddin M. A., O'Connor D. T. Chromogranin A: posttranslational modifications in secretory granules. Endocrinology. 1991 Jan;128(1):174–190. doi: 10.1210/endo-128-1-174. [DOI] [PubMed] [Google Scholar]
  3. Cetin Y., Grube D. Topology of chromogranins in secretory granules of endocrine cells. Histochemistry. 1991;96(4):301–310. doi: 10.1007/BF00271350. [DOI] [PubMed] [Google Scholar]
  4. Corti A., Gasparri A., Chen F. X., Pelagi M., Brandazza A., Sidoli A., Siccardi A. G. Characterisation of circulating chromogranin A in human cancer patients. Br J Cancer. 1996 Apr;73(8):924–932. doi: 10.1038/bjc.1996.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Corti A., Longhi R., Gasparri A., Chen F., Pelagi M., Siccardi A. G. Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains. Eur J Biochem. 1996 Jan 15;235(1-2):275–280. doi: 10.1111/j.1432-1033.1996.00275.x. [DOI] [PubMed] [Google Scholar]
  6. Curry W. J., Johnston C. F., Hutton J. C., Arden S. D., Rutherford N. G., Shaw C., Buchanan K. D. The tissue distribution of rat chromogranin A-derived peptides: evidence for differential tissue processing from sequence specific antisera. Histochemistry. 1991;96(6):531–538. doi: 10.1007/BF00267079. [DOI] [PubMed] [Google Scholar]
  7. Cussenot O., Villette J. M., Valeri A., Cariou G., Desgrandchamps F., Cortesse A., Meria P., Teillac P., Fiet J., Le Duc A. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol. 1996 Apr;155(4):1340–1343. [PubMed] [Google Scholar]
  8. Deftos L. J., Nakada S., Burton D. W., di Sant'Agnese P. A., Cockett A. T., Abrahamsson P. A. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology. 1996 Jul;48(1):58–62. doi: 10.1016/s0090-4295(96)00089-1. [DOI] [PubMed] [Google Scholar]
  9. Dillen L., De Block J., Van Lear L., De Potter W. Enzyme-linked immunosorbent assay for chromogranin A. Clin Chem. 1989 Sep;35(9):1934–1938. [PubMed] [Google Scholar]
  10. Eriksson B., Arnberg H., Oberg K., Hellman U., Lundqvist G., Wernstedt C., Wilander E. A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 1990 Feb;122(2):145–155. doi: 10.1530/acta.0.1220145. [DOI] [PubMed] [Google Scholar]
  11. Gill B. M., Barbosa J. A., Hogue-Angeletti R., Varki N., O'Connor D. T. Chromogranin A epitopes: clues from synthetic peptides and peptide mapping. Neuropeptides. 1992 Feb;21(2):105–118. doi: 10.1016/0143-4179(92)90521-w. [DOI] [PubMed] [Google Scholar]
  12. Goumon Y., Strub J. M., Moniatte M., Nullans G., Poteur L., Hubert P., Van Dorsselaer A., Aunis D., Metz-Boutigue M. H. The C-terminal bisphosphorylated proenkephalin-A-(209-237)-peptide from adrenal medullary chromaffin granules possesses antibacterial activity. Eur J Biochem. 1996 Feb 1;235(3):516–525. doi: 10.1111/j.1432-1033.1996.t01-1-00516.x. [DOI] [PubMed] [Google Scholar]
  13. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  14. Hsiao R. J., Seeger R. C., Yu A. L., O'Connor D. T. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest. 1990 May;85(5):1555–1559. doi: 10.1172/JCI114604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Iacangelo A. L., Eiden L. E. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept. 1995 Aug 22;58(3):65–88. doi: 10.1016/0167-0115(95)00069-n. [DOI] [PubMed] [Google Scholar]
  16. Konecki D. S., Benedum U. M., Gerdes H. H., Huttner W. B. The primary structure of human chromogranin A and pancreastatin. J Biol Chem. 1987 Dec 15;262(35):17026–17030. [PubMed] [Google Scholar]
  17. Metz-Boutigue M. H., Garcia-Sablone P., Hogue-Angeletti R., Aunis D. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem. 1993 Oct 1;217(1):247–257. doi: 10.1111/j.1432-1033.1993.tb18240.x. [DOI] [PubMed] [Google Scholar]
  18. O'Connor D. T., Bernstein K. N. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med. 1984 Sep 20;311(12):764–770. doi: 10.1056/NEJM198409203111204. [DOI] [PubMed] [Google Scholar]
  19. O'Connor D. T., Deftos L. J. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986 May 1;314(18):1145–1151. doi: 10.1056/NEJM198605013141803. [DOI] [PubMed] [Google Scholar]
  20. O'Connor D. T., Frigon R. P., Sokoloff R. L. Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. Hypertension. 1984 Jan-Feb;6(1):2–12. doi: 10.1161/01.hyp.6.1.2. [DOI] [PubMed] [Google Scholar]
  21. Simon J. P., Aunis D. Biochemistry of the chromogranin A protein family. Biochem J. 1989 Aug 15;262(1):1–13. doi: 10.1042/bj2620001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stridsberg M., Oberg K., Li Q., Engström U., Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995 Jan;144(1):49–59. doi: 10.1677/joe.0.1440049. [DOI] [PubMed] [Google Scholar]
  23. Strub J. M., Goumon Y., Lugardon K., Capon C., Lopez M., Moniatte M., Van Dorsselaer A., Aunis D., Metz-Boutigue M. H. Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J Biol Chem. 1996 Nov 8;271(45):28533–28540. doi: 10.1074/jbc.271.45.28533. [DOI] [PubMed] [Google Scholar]
  24. Strub J. M., Sorokine O., Van Dorsselaer A., Aunis D., Metz-Boutigue M. H. Phosphorylation and O-glycosylation sites of bovine chromogranin A from adrenal medullary chromaffin granules and their relationship with biological activities. J Biol Chem. 1997 May 2;272(18):11928–11936. doi: 10.1074/jbc.272.18.11928. [DOI] [PubMed] [Google Scholar]
  25. Syversen U., Jacobsen M. B., O'Connor D. T., Rønning K., Waldum H. L. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides. 1994 Mar;26(3):201–206. doi: 10.1016/0143-4179(94)90131-7. [DOI] [PubMed] [Google Scholar]
  26. Taupenot L., Remacle J. E., Helle K. B., Aunis D., Bader M. F. Recombinant human chromogranin A: expression, purification and characterization of the N-terminal derived peptides. Regul Pept. 1995 Mar 7;56(1):71–88. doi: 10.1016/0167-0115(95)00008-y. [DOI] [PubMed] [Google Scholar]
  27. Watkinson A., Jönsson A. C., Davison M., Young J., Lee C. M., Moore S., Dockray G. J. Heterogeneity of chromogranin A-derived peptides in bovine gut, pancreas and adrenal medulla. Biochem J. 1991 Jun 1;276(Pt 2):471–479. doi: 10.1042/bj2760471. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES